Aravive (ARAV) Competitors $0.04 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsSustainabilityTrends ARAV vs. TLPH, SNSE, KPRX, TSBX, JAGX, PHXM, CLRB, AEZS, MYNZ, and INDPShould you be buying Aravive stock or one of its competitors? The main competitors of Aravive include Talphera (TLPH), Sensei Biotherapeutics (SNSE), Kiora Pharmaceuticals (KPRX), Turnstone Biologics (TSBX), Jaguar Health (JAGX), PHAXIAM Therapeutics (PHXM), Cellectar Biosciences (CLRB), Aeterna Zentaris (AEZS), Mainz Biomed (MYNZ), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Aravive vs. Talphera Sensei Biotherapeutics Kiora Pharmaceuticals Turnstone Biologics Jaguar Health PHAXIAM Therapeutics Cellectar Biosciences Aeterna Zentaris Mainz Biomed Indaptus Therapeutics Talphera (NASDAQ:TLPH) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking. Does the media refer more to TLPH or ARAV? In the previous week, Talphera's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score. Company Overall Sentiment Talphera Neutral Aravive Neutral Does the MarketBeat Community prefer TLPH or ARAV? Aravive received 98 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 62.28% of users gave Aravive an outperform vote. CompanyUnderperformOutperformTalpheraOutperform Votes6100.00% Underperform VotesNo VotesAraviveOutperform Votes10462.28% Underperform Votes6337.72% Do institutionals & insiders have more ownership in TLPH or ARAV? 37.7% of Talphera shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 3.2% of Talphera shares are held by company insiders. Comparatively, 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, TLPH or ARAV? Talphera has higher earnings, but lower revenue than Aravive. Talphera is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalphera$281K38.50-$18.40M-$0.69-0.92Aravive$6.99M0.42-$76.32M-$0.96-0.04 Which has more risk & volatility, TLPH or ARAV? Talphera has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500. Comparatively, Aravive has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Do analysts rate TLPH or ARAV? Talphera presently has a consensus price target of $4.50, indicating a potential upside of 608.33%. Given Talphera's stronger consensus rating and higher possible upside, equities research analysts plainly believe Talphera is more favorable than Aravive.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talphera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TLPH or ARAV more profitable? Aravive's return on equity of 0.00% beat Talphera's return on equity.Company Net Margins Return on Equity Return on Assets TalpheraN/A -118.46% -65.82% Aravive N/A N/A N/A SummaryTalphera beats Aravive on 9 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Aravive News Delivered to You Automatically Sign up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARAV vs. The Competition Export to ExcelMetricAravivePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.0410.4289.5817.17Price / Sales0.42195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.225.094.774.78Net Income-$76.32M$151.83M$120.15M$225.60M7 Day PerformanceN/A-2.13%-1.92%-1.23%1 Month PerformanceN/A-3.10%11.47%3.36%1 Year PerformanceN/A11.54%30.54%16.60% Aravive Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARAVAravive0.6473 of 5 stars$0.04flatN/AN/A$2.95M$6.99M-0.0420TLPHTalphera2.886 of 5 stars$0.67+2.8%$4.50+573.6%N/A$11.38M$281,000.00-0.9419SNSESensei Biotherapeutics4.0684 of 5 stars$0.45+2.2%$4.33+863.4%-28.0%$11.31MN/A-0.3740KPRXKiora Pharmaceuticals2.1118 of 5 stars$3.64+9.6%$10.00+174.7%-32.2%$10.92M$16M0.0010Positive NewsGap UpTSBXTurnstone Biologics2.8499 of 5 stars$0.47-2.4%$2.13+353.5%-79.7%$10.84M$19.31M-0.1582JAGXJaguar Health0.2547 of 5 stars$0.91-6.1%N/A-89.7%$10.74M$9.76M0.0050News CoverageGap UpPHXMPHAXIAM TherapeuticsN/A$3.10-0.6%N/AN/A$10.58M$32.66M0.0049CLRBCellectar Biosciences1.8001 of 5 stars$0.25-4.1%$17.67+6,983.7%-90.9%$10.29MN/A-0.1510Analyst ForecastGap UpHigh Trading VolumeAEZSAeterna ZentarisN/A$5.72+5.9%N/A-65.1%$10.26M$2.37M-0.2020Analyst ForecastGap UpMYNZMainz Biomed2.5063 of 5 stars$5.10-4.9%$120.00+2,252.9%-85.7%$10.21M$917,203.00-0.0730News CoverageGap UpINDPIndaptus Therapeutics2.8713 of 5 stars$1.00+0.1%$8.50+749.4%-49.0%$10.20MN/A-0.586 Related Companies and Tools Related Companies TLPH Competitors SNSE Competitors KPRX Competitors TSBX Competitors JAGX Competitors PHXM Competitors CLRB Competitors AEZS Competitors MYNZ Competitors INDP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARAV) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aravive With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARAV Stock Alerts